COVID-19: The Ivermectin African Enigma
Rodrigo Guerrero, Luis Eduardo Bravo, Edgar Muñoz, Elvia Karina Grillo Ardila, Esteban Guerrero
Colombia médica, doi:10.25100/cm.v51i4.4613
The low frequency of cases and deaths from the SARS-CoV-2 COVID-19 virus in some countries of Africa has called our attention about the unusual behavior of this disease. The ivermectin is considered a drug of choice for various parasitic and viral diseases and shown to have in vitro effects against SARS-CoV-2.
Conflict of Interest: Two of the authors of this paper are members of the Editorial Board of Colombia Medica
Supplementary. Effect modifications using the stratified analyses according to APOC status and HDI index. In African regions with HDIs above the Z-score means, the predicted number of deaths and infections was lower in APOC countries; and in the regions with the lowest HDI score (Z-score <0), the number of deaths and infections was lower in the non-APOC countries.
References
Cepelowicz, Sherman, Fatteh, Voge, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19, medRxiv,
doi:10.1101/2020.06.06.20124461Core, R: A language and environment for statistical computing
Hdr, Human Development Report 2019: beyond income, beyond averages, beyond today: Inequalities in human development in the 21st century. United Nations Development Program
Health Organization, Global programme to eliminate lymphatic filariasis: progress report, 2018, Weekly Epidemiological Record
Jans, Wagstaff, Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells
Liu, He, Zhuang, He, Li, Unexpected positive correlation between human development index and risk of infections and deaths of COVID-19 in Italy, One Heal,
doi:10.1016/j.onehlt.2020.100174Mbow, Lell, Jochems, Cisse, Mboup et al., COVID-19 in Africa: Dampening the storm?, Science
Norrestad, Number of coronavirus tests in Iceland since
Shahbazi, Khazaei, Socio-economic inequality in global incidence and mortality rates from coronavirus disease 2019: an ecological study, New Microbes New Infect,
doi:10.1016/j.nmni.2020.100762Sharp, Corp, Over 30 Years: The Mectizan ® Donation Program
Sharun, Dhama, Patel, Pathak, Tiwari et al., Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob,
doi:10.1186/s12941-020-00368-wSodahlon, Mectizan Donation Program
Swargiary, Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies, Research Square,
doi:10.21203/rs.3.rs-73308/v1Varghese, Kaukinen, Gläsker, Bespalov, Hanski et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antiviral Res,
doi:10.1016/j.antiviral.2015.12.012Who/Apoc, The WHO African programme for onchocerciasis control final evaluation report
Worldometer, COVID-19 Coronavirus Pandemic
